双成药业
(002693)
| 流通市值：53.77亿 | | | 总市值：54.20亿 |
| 流通股本：4.11亿 | | | 总股本：4.15亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 126,959,513.71 | 94,892,601.28 | 42,761,740.63 | 235,929,899.37 |
| 营业收入 | 126,959,513.71 | 94,892,601.28 | 42,761,740.63 | 235,929,899.37 |
| 二、营业总成本 | 180,496,024.5 | 119,568,948.3 | 57,356,433.81 | 278,156,880.41 |
| 营业成本 | 50,847,128.4 | 36,287,921.27 | 17,081,015.21 | 74,855,728.77 |
| 税金及附加 | 4,345,478.04 | 2,938,352.23 | 1,499,177.36 | 6,645,529.84 |
| 销售费用 | 40,067,089.1 | 27,564,651.64 | 14,600,389.33 | 102,969,976.38 |
| 管理费用 | 68,624,361.46 | 42,684,905.07 | 19,161,921.08 | 76,259,123.16 |
| 研发费用 | 10,028,401.53 | 5,921,686.84 | 3,041,458.97 | 7,955,395.97 |
| 财务费用 | 6,583,565.97 | 4,171,431.25 | 1,972,471.86 | 9,471,126.29 |
| 其中:利息费用 | 6,679,963.79 | 4,296,458.31 | 2,002,861.33 | 9,578,791.78 |
| 其中:利息收入 | 27,788.55 | 20,407.79 | 7,628.17 | 34,482.24 |
| 加:公允价值变动收益 | 27,812.69 | -39,679.33 | -61,139.84 | -39,853,707.65 |
| 加:投资收益 | 398,789.29 | 287,842.68 | 183,105.34 | 2,753,303.96 |
| 资产处置收益 | -21,465.98 | -4,894.02 | -4,894.02 | 467,606.24 |
| 资产减值损失(新) | -348,587.98 | -291,444.56 | - | -3,551,913.1 |
| 信用减值损失(新) | 94,168.37 | -47,851.45 | -20,032.34 | -1,148,464.36 |
| 其他收益 | 2,054,828.96 | 876,443.76 | 319,026.68 | 10,406,204.98 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -51,330,965.44 | -23,895,929.94 | -14,178,627.36 | -73,153,950.97 |
| 加:营业外收入 | 1,725.74 | 1 | 1 | 564,662.28 |
| 减:营业外支出 | 34,573.85 | 27,780.59 | 12,027.17 | 378,647.02 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -51,363,813.55 | -23,923,709.53 | -14,190,653.53 | -72,967,935.71 |
| 减:所得税费用 | 234,620.9 | 296,119.69 | - | -991,593.88 |
| 六、净利润 | -51,598,434.45 | -24,219,829.22 | -14,190,653.53 | -71,976,341.83 |
| 持续经营净利润 | -51,598,434.45 | -24,219,829.22 | -14,190,653.53 | -71,976,341.83 |
| 归属于母公司股东的净利润 | -37,837,689.22 | -16,946,164.02 | -8,742,676.77 | -50,741,578.37 |
| 少数股东损益 | -13,760,745.23 | -7,273,665.2 | -5,447,976.76 | -21,234,763.46 |
| (一)基本每股收益 | -0.09 | -0.04 | -0.02 | -0.12 |
| (二)稀释每股收益 | -0.09 | -0.04 | -0.02 | -0.12 |
| 八、其他综合收益 | -545.9 | -3,161.51 | -2,853.71 | 6,375.08 |
| 归属于母公司股东的其他综合收益 | -545.9 | -3,161.51 | -2,853.71 | 6,375.08 |
| 九、综合收益总额 | -51,598,980.35 | -24,222,990.73 | -14,193,507.24 | -71,969,966.75 |
| 归属于母公司股东的综合收益总额 | -37,838,235.12 | -16,949,325.53 | -8,745,530.48 | -50,735,203.29 |
| 归属于少数股东的综合收益总额 | -13,760,745.23 | -7,273,665.2 | -5,447,976.76 | -21,234,763.46 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |